Theratechnologies Inc T.TH

So what if I told you

[SPCEO1]

that an analyst who follows TH wrote a report today and decided not to mention anything about either the financing or the phase 1a data. Instead, the analyst decided to focus their report first on Egrifta, then NASH and then Trogarzo. I have to admit that cancer did get a brief mention in the "Risk Factors" section where the analyst made this comment: "2) increased focus on drug development as TH makes

progress on its oncology assets".

Obviously, you probably think I am drunk or doinig drugs to say such a ridiculous thing! Sadly, I am completely lucid and am just reporting accurately on how the NBF analyst crafted his THTX report today. 

The blame for this is obviously partly on the analyst but it is apparent the company's failure to maintain a decent relationship with this analyst or any of the others is what leads to such absurdity in the end. You might think the analyst is really stupid but I don't think that is the case. He likely has just had it with how bad TH has been over a long period of time on engaging the capital markets and how they have let the stock price bleed out in recent months in an info vacuum by holding back that phase 1a data for months. TH could have been giving regular updates as the patients they spoke about today moved through the trial. Maybe there was a good reason to not do so, but I am not aware of it. 

$288,000 dollars worth of THTX traded hands today on the great news we got today that significantly derisked the future of the company - that is it! I am not sure how that can actually be true but the depths to which the company's engagement with the capital markets has reached is breathtaking. We thought there was a problem a year ago and two years ago and three years ago and so on. Shareholders asked for a new board memeber with expertise in the capital markets to be added, which they graciously did, but the situation, which seemed like it could not get any worse, has gotten worse still. 

It was a great day for THTX. Too bad so few investors actually noticed.

[qwerty22]

I think there's something very odd about the lack of a fanfare about oncology. They didn't knock it out of the park today but they did everything they needed to do. The separate PR was great but Christian should have walked us through it today on the CC. Something is going on, hopefully something positive.

[scarlet1967]

Well while ago I spoke to the previous IR lady and point out why such a low profile? Why not approaching the retail segment? Why not using the powerful social media platforms which are followed  by hundreds of thousands investors? Why their messaging strategy is always saving the news till the last moment? Many other whys! She instead tried to convince me her multi decade experience of

[palinc2000]

Dont worry about it....Nobody cares what  an analyst from NBF thinks... Assuming the broader markets dont crater  tomorrow I think tomorrow will see a more pronounced increase in THTX  SP ...The very few  who wanted out are now out imo ....I expect  much higher volume  also As Muxlix would say MY CALL .!!!!!

[palinc2000]

OMG my prediction for much higher volume and price has not materialized at least not this morning... I take comfort in the Chinese proverb MAKING PREDICTIONS IS VERY HARD ESPECIALLY WHEN ITS ABOUT THE FUTURE  

[Wino115]

Quite a history for that quote. I thought for sure it was Yogi Berra, but it traces to Danish physicists. https://quoteinvestigator.com/2013/10/20/no-predict/#:~:text=It%20is%20difficult%20to%20make%20predictions%2C%20especially%20about,is%20hard%20to%20prophecy%2C%20particularly%20about%20the%20future.

[palinc2000]

LOL TThanks for the link...Quite  amusing..I think the real  conclusion is that people  should not think  themselves  infallible and admit without endless argument that they were wrong!! I have been thinking all morning about why the market did not react as I expected . I think it is a vivid proof that the elusive POC has simply not been reached  yet,,,,,,BTW 

[Bucknelly21]

no one is listening and the analysts that were are asking about egrifta including ed nash, these analysts are missing the mark or not caring 

[qwerty22]

You know I'm the guy always looking for the problem. There's no set definition of POC. It's a subjective call based on thinking the data get's you there. They flirted yesterday with many statements that where as near as damn it. It doesn't make a whole lot of sense not to be more clear. I would have called it. I re-listened and tried to knit together all the statements

[palinc2000]

I dont think the company would hold back if they were convinced of or if they had a high degree of certainty that POC had been attained,,,,I suggest that maybe SPCEO could just pick p the phone and simply ask for a yes or no answer... What is clear to me is that no institutions bought yestetday and today and one would think that Soleus and others would have jumped at the oppotunity of getting in

[Momo25]

Paul Levesque seems optimistic. Big pharma and investors are not. Apparently, the preliminary results are not enough convincing. I am expecting the next 3 months will be tough on a SP valuation. No buyers, no sellers except the bank algorithms dragging the share down  It's a catch 22 situation.

[realitycheck4u]

This post has been removed in accordance with Community Policy

[qwerty22]

It has been the case that when they update the investor presentation that they've put small details  in that have clarified the situation for me. Given the loan they probably should update the presentation soon. Maybe there'll be a little extra clarity around the 1a data then. Maybe.

[SPCEO1]

If I am right about the idea that the company is about to go on acharm offensive with investors, we will be getting a nice shiny new corporate presentations soon too.

[SPCEO1]

The news we heard these last few days was outstanding. But TH let the stock price bleed out from its self-inflicted wounds of indifference, so apparently there was no one but us, who are already fully loaded with TH, who heard the news.  I get an update every morning on Twitter from something called BiopharmaCatalyst that lists all the deals, clinical trial results and financings in the

[Wino115]

Unless it was new Board member Frank Holler who introduced Marathon to THTX or helped with the deal structure, I would say a one year grade for him would be that it's been a flop.  The capital market data shows a lower price and much less average volume over the year.  He does not seem to have had any impact that is discernible to an outside shareholder.  He should be all over

[qwerty22]

my sleuthing, might be wrong Marathon recently bought an epipen developer called Kaleo https://www.fiercepharma.com/manufacturing/epipen-rival-kaleo-snapped-up-310m-deal-by-asset-management-group This woman seems to be a sales manager for Kaleo and account manager for Theratechnologies (???) https://www.linkedin.com/in/lisahelenbryant/ Evan Bedil is board member on Kaleo and he'

[qwerty22]

If you timed how long they spent talking about each part of the business it wouldn't surprise me if the most time was spent on Egrifta.

[SPCEO1]

They really are not being too smart about this and despite getting it wrong for many, many years, nothing ever changes in their approach. They should have said the bare minimum about Egrifta and when the first analyst first question was about Egrifta, Paul should have taken charge of the situation like a good politician and quickly pivoted to talking about the cancer data. Same with the second

[palinc2000]

The  growth potential of the sales of Egtifta and Trogarzo is what makes THTX a much less risky investment than im other biotechs...Paul kept referring to the 6 periods .....I think he means 6 quarters .... since his tenure???? Anyway he mentioned enrollment (?)in Egrifta up 44% and he said something like it is very uncommon for a drug to have been on the market for so long to have over 20

[qwerty22]

Egrifta has been a roller coaster. Stoppages, changing hands, reformulation. It's produced ups and downs. I'd check where on the rollercoaster we are before assigning any short term uptick to long term growth. I still don't think it's broken out the long term sales range it has been in. If he was giving solid reasons why the drug is seen different in the clinic I might believe in

[Bucknelly21]

Even ed nash started with egrifta, at this pointbthey should be held accountable per pauls words when he fist started. Ive seen zero evidence of him holding anyone accountable 

[SPCEO1]

Frankly, what Paul was saying about huge increases in patient counts, or something like that, must be poppycock in some manner as it sounds great but it is not translating into sales yet. I thought we might get a popsitive surprise in Egrifta sales in Q2 but Bloomberg led us astray again. All that being said, you might find this article of interest: https://editorialge.com/tesamorelin-injection/

[qwerty22]

If one Q they enrolled two people and the next Q they enrolled 3 people then that would be an increase of the enrolment rate of 50% Q over Q.

[SoLong]

It is funny, the stock got de-risked by at least 50%, and nothing but complaints.  I am here because as bad as they are a capital markets and communication they are good on the science.  So we didn't get a huge jump today, I now have more shares at a discount and no chance at them getting diluted at this rate.  Best conference call I've listened to in a year everything I

[CreatingApe]

Thank you for this! Thought I was the only one... Would everyone here rather have 7 mil shares traded by algo's up 40 percent pre market and then in the red by the end of the day? I believe the up tick in volume and climbing share price will continue. Like the run up to Trogarzo approval. With some bigger jumps as we get further into the trial and more data/partnerships are released

[palinc2000]

The math works also from 20 to 30 !!! I know that I am almodt alone in my camp pushing and believing that we are still in the midst of launching the 2 drugs which has a terrible execution upon the original launch and when Paul theLauncher in Chief joined the pandemic put a halt in the relaunch for two years So we are now at the start of the re launch and I still feel that the market undervalues